Top 5 Performing Biotech Stocks Of 2014
Stocks that have performed the best so far this year may very well end up being the ones that continue to outperform in the near term.
With that being said, it couldn't hurt for investors and traders to seek out the best performing stocks year to date. Below is a list of the top five biotech stocks so far in 2014.
The stock coming in at number five is bluebird bio Inc (NASDAQ: BLUE).
Bluebird was sitting around $21 per share at the start of the year but was trading Wedesday around $38.70. For 2014, bluebird is up 83 percent.
Next up is Puma Biotechnology Inc (NYSE: PBYI).
Puma had just cleared the $100 mark at the end of 2013, but after the first eight months of 2014 the stock is now trading at $255.60. That gives Puma a 152 percent gain on the year.
Coming in third is the recently popular Ebola stock, Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR).
Tekmira has been all over the place as of late, but the stock started the year at just under $8 per share. After a 135 percent gain, the stock is now trading at $18.77.
Runner up for the best-performing biotech stock thus far is Amicus Therapeutics, Inc. (NASDAQ: FOLD).
Amicus wasn't even a $2 stock at the beginning of 2014, but after a rise of 198 percent the stock was recently trading north of $7 per share.
And the top performance by a biotech stock in 2014 is Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN).
Achillion started 2014 at $3.32 per share and traded recently at $12.86. That gives the stock a whopping gain of 287 percent.
Momentum seems to be with the biotech stocks again as of late. The stocks listed above, which have been the biggest gainers year to date, certainly warrant a look as 2014 comes into the final stretch.
The screening criterion utilized to identify these five stocks was one that isolated biotech stocks trading more than $5 per share and traded at least 500,000 shares per day (90-day average volume).
Investors should always conduct their own due diligence before investing in any stock. However, biotech stocks that have performed the best could very well continue to move higher.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.